Bispecific Antibody Market Forecast And Strategies To 2025

Bispecific Antibody Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

"Global Bispecific Antibody market is valued at USD 457.5 Million in 2018 and expected to reach USD 697.5 Million by 2025 with the CAGR of 6.21% over the forecast period."

Bispecific antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Most of the bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The benefits of bispecific antibodies over monoclonal therapeutics are due to their higher binding avidity to targets, which can interact with more than one surface antigen and boosted cytotoxic effects.

Key Players for Global Bispecific Antibody Market Report–

Global Bispecific Antibody market Report covers prominent players are like Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc., Portola Pharmaceuticals, Inc., Sanofi S.A. and others.

North America is Expected to Dominate the Global Bispecific Antibody Market

North America is expected to dominate the global bispecific antibody market due to growing incidences of cancer such as lung cancer, cervical cancer, breast cancer, and prostate cancer. According to national cancer institute, in 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease. Europe is considered as an emerging market in bispecific antibodies treatment due to growing market penetration in this region. Advances in biotechnology leading to improved antibody production and recombination techniques have fueled the development of antibodies and myriad antibody constructs. Also Asia Pacific market growth is attributed to the presence of untapped opportunities due to extensive improvement in the healthcare infrastructure in this region.

Key Benefits for Global Bispecific Antibody Market Report–

• Global market report covers in depth historical and forecast analysis.
• Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
• Global market report helps to identify opportunities in market place.
• Global market report covers extensive analysis of emerging trends and competitive landscape.

Bispecific Antibody Market Segmentation:–

By Type:

• Catumaxomab (Removab)
• Blinatumomab
• Duligotumab
• SAR 156597

By Applications:

• BsMAb for Cancer Diagnostic
• BsMAb for Diagnosis of Bacterial & Infectious Diseases
• BsAbs Blocking Signaling Pathways
• BsAbs Targeting Tumor Angiogenesis
• Specific Delivery of Effector Compounds to Targets
• Bispecific Antibodies and Gene Therapy

Get Sample Copy of This Premium Report@https://brandessenceresearch.com/requestSample/PostId/1129